VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
UTIUniversal Technical Institute, Inc.
$41.59$2.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksUTIFinancials

Universal Technical Institute, Inc. (UTI) Financials

26Y historyFree accessUpdated daily

Operating income plummeted to $339,000 in 2026Q2, reflecting extreme sensitivity to cost fluctuations as operating margins compressed to a razor-thin 0.2%.

UTI Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMSep'25Sep'24Sep'23Sep'22Sep'21Sep'20Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10Sep'09Sep'08Sep'07Sep'06Sep'05Sep'04Sep'03Sep'02Sep'01Sep'00
Sales/Revenue868.99M835.62M732.69M607.41M418.76M335.08M300.76M331.5M316.96M324.26M347.15M362.67M378.39M380.27M413.55M451.9M435.92M366.63M343.46M353.37M347.07M310.8M255.15M196.5M144.37M109.49M92.08M
Revenue Growth %11.03%14.05%20.63%45.05%24.97%11.41%-9.27%4.59%-2.25%-6.59%-4.28%-4.15%-0.49%-8.05%-8.49%3.67%18.9%6.75%-2.8%1.82%11.67%21.81%29.85%36.1%31.86%18.91%-
Cost of Goods Sold439.35M420.49M384.53M329.87M207.23M166.82M155.93M178.32M182.59M181.03M194.4M194.42M200.05M199.54M211.98M223.47M212.58M193.49M186.64M186.25M173.23M145.03M116.73M92.44M70.81M59.55M48.52M
COGS % of Revenue-50.32%52.48%54.31%49.49%49.78%51.85%53.79%57.61%55.83%56%53.61%52.87%52.47%51.26%49.45%48.77%52.77%54.34%52.71%49.91%46.66%45.75%47.05%49.05%54.39%52.7%
Gross Profit209.47M415.13M348.16M277.54M211.53M168.26M144.83M153.19M134.38M143.24M152.75M168.26M178.34M180.73M201.57M228.43M223.34M173.15M156.82M167.13M173.84M165.77M138.42M104.05M73.56M49.94M43.56M
Gross Margin %24.11%49.68%47.52%45.69%50.51%50.22%48.15%46.21%42.39%44.17%44%46.39%47.13%47.53%48.74%50.55%51.23%47.23%45.66%47.29%50.09%53.34%54.25%52.95%50.95%45.61%47.3%
Gross Profit Growth %-19.23%25.45%31.2%25.71%16.18%-5.46%14%-6.19%-6.23%-9.22%-5.65%-1.32%-10.34%-11.76%2.28%28.99%10.41%-6.17%-3.86%4.86%19.76%33.03%41.45%47.3%14.65%-
Operating Expenses368.08M331.66M289.27M256.14M189.16M153.32M148.7M160.99M169.65M145.06M171.37M165.12M172M174.8M187.46M183.33M176.79M154.5M146.12M143.38M133.1M110M88.3M67.9M51.54M38.33M33.89M
OpEx % of Revenue-39.69%39.48%42.17%45.17%45.76%49.44%48.56%53.52%44.74%49.37%45.53%45.46%45.97%45.33%40.57%40.56%42.14%42.54%40.57%38.35%35.39%34.61%34.55%35.7%35.01%36.81%
Selling, General & Admin368.08M331.66M289.27M256.14M183.26M152.52M148.7M160.99M169.65M141.54M167.68M201.25M164.81M165.39M176.49M183.33M176.79M154.5M146.12M143.38M133.1M110M88.3M67.9M51.54M38.33M33.89M
SG&A % of Revenue-39.69%39.48%42.17%43.76%45.52%49.44%48.56%53.52%43.65%48.3%55.49%43.56%43.49%42.68%40.57%40.56%42.14%42.54%40.57%38.35%35.39%34.61%34.55%35.7%35.01%36.81%
Research & Development000000000000000000000000000
R&D % of Revenue---------------------------
Other Operating Expenses00005.9M800K01.47M1.08M1.09M-49K140K563K655K10.97M000000000000
Operating Income55.16M83.47M58.89M21.4M22.37M14.95M-2.58M-7.8M-35.27M-1.82M-18.62M-9.22M6.34M5.93M14.12M45.1M46.55M18.64M10.7M23.75M40.74M55.78M50.12M36.16M22.02M11.61M9.66M
Operating Margin %6.35%9.99%8.04%3.52%5.34%4.46%-0.86%-2.35%-11.13%-0.56%-5.36%-2.54%1.67%1.56%3.41%9.98%10.68%5.08%3.11%6.72%11.74%17.95%19.64%18.4%15.25%10.6%10.49%
Operating Income Growth %-41.73%175.2%-4.36%49.69%678.44%66.88%77.88%-1833.94%90.21%-101.92%-245.54%6.88%-57.99%-68.71%-3.1%149.72%74.26%-54.96%-41.7%-26.96%11.28%38.63%64.21%89.7%20.12%-
EBITDA78.16M140.25M110.08M67.22M55.15M44.58M34.84M9.49M-18.2M16.34M468K9.93M26.81M28.09M37.93M69.95M66.44M36.21M28.3M42.5M54.95M65.56M58.93M42.54M26.97M16.14M13.55M
EBITDA Margin %8.99%16.78%15.02%11.07%13.17%13.3%11.58%2.86%-5.74%5.04%0.13%2.74%7.09%7.39%9.17%15.48%15.24%9.88%8.24%12.03%15.83%21.09%23.1%21.65%18.68%14.74%14.72%
EBITDA Growth %-40.47%27.42%63.76%21.88%23.71%27.96%267.15%152.13%-211.36%3392.52%-95.29%-62.96%-4.54%-25.96%-45.77%5.28%83.48%27.94%-33.41%-22.65%-16.18%11.23%38.54%57.75%67.09%19.11%-
D&A (Non-Cash Add-back)23M56.78M51.19M45.82M32.78M29.63M37.42M17.29M17.07M18.17M19.09M19.16M20.47M22.16M23.82M24.84M19.89M17.57M17.61M18.75M14.21M9.78M8.81M6.38M4.95M4.53M3.89M
EBIT57.8M89.91M65.7M27.74M22.25M15.46M-2.58M-4.45M-32.39M650K-18.09M-8.34M6.34M6.03M15.1M45.65M47.29M19.35M10.7M23.75M40.74M55.78M50.12M36.16M22.02M11.61M9.66M
Net Interest Income1.06M540K-3.16M-3.79M-1.5M-282K1.14M-1.73M-1.89M-2.48M-3.2M-2.13M-1.62M234K302K252K250K198K000000000
Interest Income5.39M6.17M6.31M5.86M507K83K1.15M1.49M1.43M900K243K215K223K234K306K258K259K246K000000000
Interest Expense190K5.63M9.47M9.66M2M365K10K3.22M3.31M3.38M3.44M2.34M1.85M04K6K9K48K000000000
Other Income/Expense1.34M805K-2.66M-3.31M-1.93M236K1.28M137K-422K-907K-2.9M-1.46M-590K889K847K543K729K664K3.32M2.62M2.97M1.46M-2.17M-3.42M-7.1M-10.67M-11.88M
Pretax Income56.51M84.27M56.23M18.09M20.44M15.18M-2.59M-7.67M-35.7M-2.73M-21.53M-10.68M5.75M6.82M14.96M45.65M47.28M19.3M14.02M26.37M43.71M57.24M47.96M32.73M14.92M933K-2.21M
Pretax Margin %6.5%10.09%7.67%2.98%4.88%4.53%-0.86%-2.31%-11.26%-0.84%-6.2%-2.95%1.52%1.79%3.62%10.1%10.85%5.27%4.08%7.46%12.59%18.42%18.8%16.66%10.33%0.85%-2.4%
Income Tax13.93M21.26M14.23M5.76M-5.41M602K-10.6M203K-3.02M5.4M26.17M-1.53M3.71M3.01M5.93M18.41M18.45M7.57M5.8M10.81M16.32M21.42M19.14M12.35M5.23M10.67M34.01M
Effective Tax Rate %24.65%25.22%25.3%31.87%-26.45%3.96%408.71%-2.65%8.45%-197.62%-121.57%14.34%64.56%44.12%39.63%40.33%39.03%39.22%41.4%40.98%37.35%37.42%39.9%37.74%35.05%1143.84%-1535.95%
Net Income42.68M63.02M42M12.32M25.85M14.58M8.01M-7.87M-32.68M-8.13M-47.7M-9.15M2.04M3.81M9.03M27.24M28.83M11.73M8.22M15.56M27.39M35.82M28.82M20.38M9.69M-9.74M-36.22M
Net Margin %4.91%7.54%5.73%2.03%6.17%4.35%2.66%-2.37%-10.31%-2.51%-13.74%-2.52%0.54%1%2.18%6.03%6.61%3.2%2.39%4.4%7.89%11.52%11.3%10.37%6.71%-8.89%-39.34%
Net Income Growth %-25.68%50.04%240.86%-52.33%77.27%82.08%201.78%75.93%-302.09%82.96%-421.32%-549.14%-46.54%-57.82%-66.84%-5.52%145.7%42.81%-47.21%-43.17%-23.54%24.29%41.42%110.33%199.49%73.11%-
Net Income (Continuing)42.25M63.02M42M12.32M25.85M14.58M8.01M-7.87M-32.68M-8.13M-47.7M-9.15M2.04M3.81M9.03M26.9M28.83M11.73M8.22M15.56M27.39M35.82M28.82M20.38M9.69M-9.74M-36.22M
Discontinued Operations000000000000000000000000000
Minority Interest000000000000000000000000000
EPS (Diluted)0.771.130.750.130.380.170.05-0.31-1.30-0.33-1.96-0.380.080.150.361.101.180.480.320.570.971.261.040.790.44-0.73-2.70
EPS Growth %-26.01%50.67%476.92%-65.79%123.53%218.35%117.23%76.15%-293.94%83.16%-415.79%-575%-46.67%-58.33%-67.27%-6.78%145.83%50%-43.86%-41.24%-23.02%21.15%31.65%79.55%160.27%72.96%-
EPS (Basic)-1.160.770.130.390.170.05-0.31-1.30-0.33-1.96-0.380.080.160.371.121.200.480.320.580.991.281.141.030.51-0.73-2.70
Diluted Shares Outstanding55.73M55.62M50.85M34.48M33.74M33.12M30.11M25.44M25.11M24.71M24.31M24.39M24.92M24.7M24.94M24.74M24.51M24.63M25.81M27.42M28.25M28.54M27.59M25.05M20.24M13.4M13.43M
Basic Shares Outstanding54.8M54.3M49.43M33.98M33.22M32.77M29.81M25.44M25.11M24.71M24.31M24.08M24.64M24.52M24.71M24.43M24.04M24.25M25.57M26.77M27.8M27.9M24.66M13.54M13.4M13.4M13.43M
Dividend Payout Ratio------1.24%-----484.78%257.74%82.21%133.39%126.03%-----43.57%24.54%---

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Regulatory Title IV dependency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Growth Momentum Faces Headwinds

As reported in recent financial filings, UTI's year-over-year revenue growth has decelerated to 6.7% in 2026Q2, a notable decline from the double-digit expansion observed throughout 2025, suggesting that the initial tailwinds from the Concorde acquisition and post-pandemic enrollment recovery may be losing their primary momentum.

The deceleration in top-line growth warrants caution, as it may indicate that the company is reaching a saturation point in its core transportation markets. Investors should monitor whether the healthcare segment can provide sufficient organic growth to offset the cooling demand in legacy vocational programs.

Gross Margin Compression Signals Pressure

According to the latest income statement data, UTI's gross margin experienced a sharp contraction to -49.6% in 2026Q2, representing a significant deviation from the historical 47% to 50% range and suggesting potential volatility in the underlying cost of delivering specialized, lab-intensive educational services.

This sudden margin collapse appears highly anomalous and requires immediate investigation into whether this reflects a one-time accounting adjustment or a structural shift in instructional costs. Such a drastic swing suggests that the company's high fixed-cost model is currently failing to absorb operational expenses effectively.

Operating Leverage Remains Highly Sensitive

Based on the provided quarterly figures, UTI's operating income plummeted to $339,000 in 2026Q2, illustrating that the company's profitability is extremely sensitive to minor fluctuations in revenue and SG&A, as the operating margin compressed to a razor-thin 0.2% from previous double-digit levels.

The inability to maintain operating leverage during a period of positive revenue growth suggests that SG&A expenses are not scaling efficiently with the business. This lack of scalability may indicate that the integration of new divisions is creating persistent overhead burdens that erode bottom-line performance.

Earnings Quality Obscured by Volatility

As indicated by the 2026Q2 results, UTI's net income of $433,000 and EPS of $0.01 highlight a significant deterioration in earnings quality, as the company struggles to translate revenue into consistent shareholder value amidst rising operational costs and potential non-operating items impacting the bottom line.

The sharp drop in EPS compared to prior quarters suggests that the company's earnings power is currently fragile and susceptible to operational friction. Investors should look past the headline revenue figures to determine if the current earnings profile is sustainable or merely a reflection of temporary integration-related inefficiencies.

Structural Risks to Profitability Narrative

While management emphasizes a diversified platform, the 2026Q2 income statement suggests that UTI's business model remains vulnerable to cost spikes, as evidenced by the sudden erosion of gross margins and the near-total disappearance of operating income despite continued, albeit slower, top-line revenue growth.

Short-sellers may focus on the company's inability to protect margins, arguing that the high-touch vocational model is inherently difficult to scale profitably. The reliance on federal funding combined with these margin pressures suggests that any regulatory tightening could lead to a rapid deterioration in financial health.

UTI — Frequently Asked Questions

Quick answers to the most common questions about buying UTI stock.

What was Universal Technical Institute, Inc.'s (UTI) revenue in 2025?

For fiscal year 2025, Universal Technical Institute, Inc. (UTI) reported total revenue of $835.6M. This represents a 807.5% increase compared to $92.1M in 2000.

Is Universal Technical Institute, Inc. (UTI) profitable?

Universal Technical Institute, Inc. (UTI) is profitable, generating $63.0M in net income for the fiscal year ending 2025 with a net profit margin of 7.5%.

What is Universal Technical Institute, Inc.'s operating profit margin?

Universal Technical Institute, Inc. (UTI) reported an operating income of $83.5M, resulting in an operating profit margin of 10.0%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Universal Technical Institute, Inc.'s gross profit and gross margin?

Universal Technical Institute, Inc. (UTI) generated $415.1M in gross profit for the year, representing a gross profit margin of 49.7%. This demonstrates the company's core pricing power and production efficiency.